PreprintAll rights reservedbioRxiv23 Oct 2026

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

B. Ziccheddu
C. Savid-Frontera
V. V. G. Saralamma
C. Gatenbee
A. A. Youssfi
M. Chojnacka
M. Menges
L. Cuadrado-Delgado
M. Durante
J. Mullinax
K. Reid
J. A. Miranda

19 more authors

S. Corallo
E. Merritt
W. Sawyer
A. Augello
A. D. Newsam
D. Chahar
C. Amador
J. Y. Spiegel
M. Davila
O. Landgren
J. P. Alderuccio
M. Robertson-Tessi
R. Atkins
S. Usmani
M. D. Jain
A. R. A. Anderson
F. Maura¹
J. H. Schatz
F. L. Locke

¹Memorial Sloan Kettering Cancer Center

Read full text PDF DOI Cite

Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma
Danielle S. Wallace, Yashashree Gupta, Carla Casulo +1
HemaSphere1 Nov 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lucas Brehm, Philipp Schindler, Christian Römer +11
Hematological oncology1 Nov 2026Peer-reviewedCC BYFull textOncologyEurope PMCPMC
[Phenotypic and functional changes in endogenous T cells during the bystander effect in different disease states of lymphomas treated with CD19-targeted chimeric antigen receptor T cells].
F Yan, D H Tang, W W Li +4
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi1 Aug 2026Peer-reviewedCC BYFull textOncologyEurope PMC
Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.
Shisen Wang, Wenbing Liu, Ying Wang +10
Cancer medicine1 Oct 2026Peer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
A REAL-WORLD STUDY OF THE EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOLLOWING TAFASITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Narendranath EPPERLA, Kim SAVERNO, Irina PIVNEVA +5
Hematology, Transfusion and Cell Therapy23 Oct 2026Peer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeX RIS

BibTeX

@misc{ziccheddu2026lymphoma,
  title = {{Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells}},
  author = {B. Ziccheddu and C. Savid-Frontera and V. V. G. Saralamma and C. Gatenbee and A. A. Youssfi and M. Chojnacka and M. Menges and L. Cuadrado-Delgado and M. Durante and J. Mullinax and K. Reid and J. A. Miranda and S. Corallo and E. Merritt and W. Sawyer and A. Augello and A. D. Newsam and D. Chahar and C. Amador and J. Y. Spiegel and M. Davila and O. Landgren and J. P. Alderuccio and M. Robertson-Tessi and R. Atkins and S. Usmani and M. D. Jain and A. R. A. Anderson and F. Maura and J. H. Schatz and F. L. Locke},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.23.761341},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.23.761341v1},
}

RIS

TY  - UNPB
TI  - Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells
AU  - B. Ziccheddu
AU  - C. Savid-Frontera
AU  - V. V. G. Saralamma
AU  - C. Gatenbee
AU  - A. A. Youssfi
AU  - M. Chojnacka
AU  - M. Menges
AU  - L. Cuadrado-Delgado
AU  - M. Durante
AU  - J. Mullinax
AU  - K. Reid
AU  - J. A. Miranda
AU  - S. Corallo
AU  - E. Merritt
AU  - W. Sawyer
AU  - A. Augello
AU  - A. D. Newsam
AU  - D. Chahar
AU  - C. Amador
AU  - J. Y. Spiegel
AU  - M. Davila
AU  - O. Landgren
AU  - J. P. Alderuccio
AU  - M. Robertson-Tessi
AU  - R. Atkins
AU  - S. Usmani
AU  - M. D. Jain
AU  - A. R. A. Anderson
AU  - F. Maura
AU  - J. H. Schatz
AU  - F. L. Locke
PY  - 2026
DA  - 2026/10/23
PB  - bioRxiv
DO  - 10.64898/2026.10.23.761341
UR  - https://www.biorxiv.org/content/10.64898/2026.10.23.761341v1
ER  -

Related

Cite